PHAXIAM THERAPEUTICS S.A.

Highlights PHAXIAM Therapeutics S.A.

Equities

PHXM

FR001400K4B1

End-of-day quote Euronext Paris Other stock markets 06:00:00 2024-05-05 pm EDT			5-day change	1st Jan Change
2.925 ^EUR	+1.74%		-1.18%	-36.41%

Apr. 15	Phaxiam initiates trial in infective endocarditis	CF
Apr. 15	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Phaxiam initiates trial in infective endocarditis	Apr. 15	CF
PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	Apr. 15	CI
PHAXIAM Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
PHAXIAM Therapeutics Completes Delisting of ADS From Nasdaq	Mar. 11	MT
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...	Feb. 21
Phaxiam to delist ADS from Nasdaq in March	Feb. 21	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW